Soligenix (SNGX) Other Operating Expenses (2010 - 2020)
Soligenix's (SNGX) quarterly Other Operating Expenses came in at $5.0 million in Q1 2020, up 210.17% YoY from $1.6 million in Q2 2019, and up 210.17% on a QoQ basis from $1.6 million in Q1 2019.
Soligenix (SNGX) Other Operating Expenses (2010 - 2020) Analysis & Trends
Soligenix (SNGX) has 5 years of Other Operating Expenses data on file, last reported at $5.0 million in Q1 2020.
- Quarterly Other Operating Expenses rose 210.17% year-over-year to $5.0 million in Q1 2020, while the trailing twelve-month figure through Dec 2020 was $5.0 million (up 210.17% YoY) and the FY2016 annual result came in at $390599.0, changed N/A from the prior year.
- Other Operating Expenses improved to $5.0 million in Q1 2020, from $1.6 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $5.0 million in Q1 2020 to a low of $1.6 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 5.00 Mn |
| Mar 31, 2019 | 1.61 Mn |
| Sep 30, 2014 | 4.00 Mn |
| Jun 30, 2011 | -25,198.00 |
| Jun 30, 2010 | 39,948.00 |